title: [Therapeutic outcomes of anti-tuberculosis treatment in the context of HIV-tuberculosis co-infection: Cohort of Kabinda Center in Kinshasa, Democratic Republic of Congo].
abstract: BACKGROUND
  The study aimed to determine the clinical forms of tuberculosis and therapeutic outcome of anti-tuberculosis treatment in the context of HIV-tuberculosis co-infection.
  
  
  METHODS
  A retrospective cohort of 120 HIV-positive patients with tuberculosis and 297 HIV-negative patients with tuberculosis attending the Kabinda Center was followed from 2010 to June, 30th 2013. The logistic regression model identified the determinants of a defavorable outcome after initiation of tuberculostatics.
  
  
  RESULTS
  The proportion of female patients was higher in the co-infected group compared with the non-co-infected group (60.8% versus 42.7%, P<0.001). HIV-seropositive patients had more forms of pulmonary smear-negative (39.2% versus 25.3%, P<0.002) and extra-pulmonary (38% versus 35%, P<0.002) tuberculosis than HIV-negative patients. HIV-positive serology (OR: 3.13, 95%CI: 1.72-5.69) and age of patients more than 41 years (OR: 3.15, 95%CI: 1.36-7.29) were associated with an unfavorable outcome.
  
  
  CONCLUSIONS
  This study highlights the usefulness of a systematically determining immunological status in co-infected patients and a timely and systematic ARV treatment, together with early diagnosis of tuberculosis. It also emphasizes the importance of adherence to support measures in order to improve tuberculosis treatment outcomes in co-infected patients.
authors.affiliation: École de santé publique, université de Kinshasa, PB 11850, Kinshasa, République démocratique du Congo. Electronic address: dakza2001@yahoo.fr.
authors.forename: P Z
authors.initials: PZ
authors.lastname: Akilimali
authors.affiliation: École de santé publique, université de Kinshasa, PB 11850, Kinshasa, République démocratique du Congo.
authors.forename: J M K
authors.initials: JM
authors.lastname: Tshilumbu
authors.affiliation: École de santé publique, université de Kinshasa, PB 11850, Kinshasa, République démocratique du Congo.
authors.forename: A K
authors.initials: AK
authors.lastname: Mavila
authors.affiliation: École de santé publique, université de Kinshasa, PB 11850, Kinshasa, République démocratique du Congo.
authors.forename: D K
authors.initials: DK
authors.lastname: Kaba
mesh_terms: D000328:Adult; D000995:Antitubercular Agents / Q000627:therapeutic use*; D060085:Coinfection / Q000188:drug therapy* / Q000453:epidemiology; D015023:Democratic Republic of the Congo / Q000453:epidemiology; D005260:Female; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy* / Q000453:epidemiology; D015497:HIV-1; D006801:Humans; D008297:Male; D012189:Retrospective Studies; D016896:Treatment Outcome; D014376:Tuberculosis / Q000150:complications / Q000188:drug therapy* / Q000453:epidemiology; D055815:Young Adult
chemical_list: D000995:Antitubercular Agents
keywords: Co-infection TB-VIH; Extra-pulmonary tuberculosis; HIV-tuberculosis co-infection; Issue thérapeutique.; Pulmonary tuberculosis smear-negative; Therapeutic outcomes; Tuberculose extra-pulmonaire; Tuberculose pulmonaire à bacilloscopie négative; Tuberculose pulmonaire à bacilloscopie positive